We are investigating Galapagos NV (GLPG) (“Galapagos” or the “Company”) for potential violations of the federal securities laws. On August 18, 2020, Galapagos disclosed that Galapagos’s collaborative partner, Gilead Sciences, Inc. (“Gilead”), had received a Complete Response Letter from the U.S. Food and Drug Administration (“FDA”) for the New Drug Application (“NDA”) for filgotinib, an investigational treatment for moderately to severely active rheumatoid arthritis. Galapagos advised investors that “[t]he FDA has requested data from the MANTA and MANTA-RAy studies before completing its review of the NDA. The MANTA and MANTA-RAy studies are designed to assess whether filgotinib has an impact on sperm parameters. The FDA also has expressed concerns regarding the overall benefit/risk profile of the filgotinib 200 mg dose.” On this news, Galapagos’s stock price fell $47.07 per share, or 25.03%, to close at $141.00 per share on August 19, 2020.